United States

IsoRay Inc (ISR.A)

ISR.A on American Stock Exchange

12:03pm EDT
Change (% chg)

$-0.00 (-0.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Isoray Inc's unit enters into consignment agreement
Thursday, 31 Aug 2017 06:29am EDT 

Aug 31 (Reuters) - Isoray Inc :Isoray says ‍on Aug 25, Isoray Medical, a unit of co, entered into a consignment agreement with Medikorpharma-Ural LLC - SEC filing​.Additionally, on August 25, 2017, Medical entered into a service agreement with Medikor.Pursuant to consignment agreement, unit consigned its inventory of enriched barium carbonate to Medikor​.Pursuant to service agreement, Medical will perform certain qualitative and quantitative chemical analyses on resulting Cesium 131.Pursuant to service agreement, unit will be paid by Medikor $140.00 per curie of Cesium-131 for which services are provided​.Medical anticipates obtaining enough Cesium-131 under arrangement to obtain over 4,000 curies of Cesium-131 over a ten-year period​.  Full Article

IsoRay Q4 revenue rises 22 pct to $1.37 mln
Friday, 4 Aug 2017 08:00am EDT 

Aug 4 (Reuters) - Isoray Inc :Isoray announces preliminary fourth quarter f2017 revenue of $1.37 million, 22% year-over-year increase.Q4 revenue rose 22 percent to $1.37 million.  Full Article

Isoray receives FDA response to application for Gammatile
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Isoray Inc :Isoray receives FDA response to 510(k) application for Gammatile.Has received a response from FDA regarding company's pending application for Gammatile radiation therapy system.FDA indicated need for co, co-applicant, to submit additional data within next 180 days as condition of securing clearance for novel Gammatile device.As a result of FDA's response, pending ntap application, which requires an FDA cleared product, will be resubmitted in fall of 2017.Completion of additional testing anticipated by end of 2017, project potential 510(k) clearance of Gammatil product in first half of 2018.  Full Article

IsoRay Q3 loss per share $0.02
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Isoray Inc :Isoray announces third quarter fiscal 2017 financial results.Q3 loss per share $0.02.Q3 revenue rose 7 percent to $1.28 million.Isoray inc - had cash, cash equivalents and certificates of deposit of $10.4 million as of march 31, 2017.  Full Article

IsoRay Q2 loss per share $0.03
Wednesday, 8 Feb 2017 04:05pm EST 

IsoRay Inc : Says continues to expect stronger second half of fiscal 2017 . IsoRay announces second quarter fiscal 2017 financial results . Q2 loss per share $0.03 .Q2 revenue fell 14 percent to $1.03 million.  Full Article

Isoray to pay $3.5 mln to settle shareholder litigation
Tuesday, 27 Sep 2016 06:00am EDT 

IsoRay Inc : Isoray, Inc enters into agreement to settle class action shareholder litigation . Entered into stipulation of settlement pursuant to which co, former CEO agreed to settle consolidated securities class action litigation . Defendants have agreed to settlement to eliminate uncertainty, distraction, burden, and expense of further litigation .Payment of $3.54 million will be made for benefit of settlement class, which Isoray expects to be funded entirely by insurance carriers.  Full Article

Isoray Q3 loss per share $0.02
Tuesday, 10 May 2016 04:49pm EDT 

Isoray Inc : Q3 loss per share $0.02 . Isoray announces third quarter fiscal 2016 financial results and early conclusions from ongoing strategic review process .Q3 revenue rose 3.5 percent to $1.2 million.  Full Article

IsoRay Inc Chairman and CEO Dwight Babcock to retire
Thursday, 7 Jan 2016 08:00am EST 

IsoRay Inc:Says Chairman and CEO Dwight Babcock to retire.Company conducts a search for a new CEO, Bill Cavanagh will serve as interim CEO.Tom LaVoy, Chair of the Company's Audit Committee, was appointed the new Chairman of the Board.  Full Article

BRIEF-Isoray Inc's unit enters into consignment agreement

* Isoray says ‍on Aug 25, Isoray Medical, a unit of co, entered into a consignment agreement with Medikorpharma-Ural LLC - SEC filing​